Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Experimental paracetamol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Experimental paracetamol formulation | EXPERIMENTAL | experimental formulation |
| paracetamol marketed formulation | ACTIVE_COMPARATOR | Paracetamol marketed formulation |
| Name | Type | Description |
|---|---|---|
| Experimental paracetamol | DRUG | experimental paracetamol with caffeine |
| Paracetamol marketed formulation | DRUG | marketed formulation containing caffeine |
Inclusion Criteria: * Healthy volunteer Exclusion Criteria: \-
Experimental paracetamol is an investigational small molecule being studied for the treatment of tension-type headache and in healthy subjects. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
Experimental paracetamol is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK.
Experimental paracetamol is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and pharmacokinetics.
Experimental paracetamol has been studied in two completed Phase 1 clinical trials: NCT01476176, a pharmacokinetic study in patients with tension-type headache, and NCT01476189, a study comparing the pharmacokinetic profile of two paracetamol formulations in healthy subjects.
Experimental paracetamol is an investigational formulation of paracetamol, also known as acetaminophen. It is being studied to evaluate its pharmacokinetic profile compared to other paracetamol formulations.